| Document |
Document Title |
|
WO/2021/172887A1 |
The present invention relates to a novel compound having a histone deacetylase 6 (HDAC6) inhibitory activity, an isomer thereof or a pharmaceutically acceptable salt thereof, the use thereof for preparing a therapeutic medicament; a phar...
|
|
WO/2021/173702A1 |
Methods of treating a cancer or a tumor in a subject using a composition are provided. The composition includes a therapeutically effective amount of 2,4-disulfonyl a-phenyl tert-butyl nitrone (2,4-ds-PBN) or pharmaceutically acceptable ...
|
|
WO/2021/173999A1 |
The disclosure relates to methods of enhancing aqueous humor outflow via the conventional outflow tract in the eye in a subject in need thereof, or reducing intraocular pressure in a subject in need thereof.
|
|
WO/2021/166899A1 |
The present invention provides a drug having excellent preventive, alleviating, and/or therapeutic effects against disease such as obesity and diabetes. Specifically, the present invention provides a gastric protease inhibitor-containing...
|
|
WO/2021/165685A1 |
The invention relates to the use of vectors to improve vision by restoring RPE phagocytosis of photoreceptor outer segments in a patient suffering from retinal dysfunction and/or degeneration.
|
|
WO/2021/167120A1 |
The present invention relates to an anti-allergy composition for atopic dermatitis alleviation or skin regeneration, containing guaiyl acetate as an active ingredient and, more particularly, to a composition for preventing or treating al...
|
|
WO/2021/164351A1 |
The present invention provides a small molecular compound of a NO donor. The small molecular compound is characterized in that the small molecular compound is a compound represented by a structural formula I or a stereoisomer, a geometri...
|
|
WO/2021/168350A1 |
The disclosure provides, inter alia, methods of reducing eye redness and/or increasing eye whiteness using alpha-2-adrenergic receptor agonists.
|
|
WO/2021/168239A1 |
A population of polymeric particles for controlled release of therapeutic agents which have unacceptable toxicity when administered intravitreally can be safely administered suprachoroidally at the same intravitreal concentration or dose...
|
|
WO/2021/165369A1 |
The present invention relates to methods for treating or preventing vascularisation in one or both corneas of a subject. The methods comprise topically administering an effective amount of a composition comprising dasatinib to one or bot...
|
|
WO/2021/167121A1 |
The present invention relates to a composition for allergy prevention, atopic dermatitis alleviation, or skin regeneration, comprising nonane as an active ingredient and, more specifically, to a composition for preventing or treating all...
|
|
WO/2021/165876A1 |
The present inventions relates to a method for vision restoration comprising the steps of expressing a temperature-sensitive transient receptor potential (TRP) channel having an extracellular tag in the retina of a subject and of contact...
|
|
WO/2021/168349A1 |
Methods of using the alpha-2-adrenergic receptor agonist of Formula (I): for improving vision such as in the treatment of ocular conditions such as presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and some fo...
|
|
WO/2021/165206A1 |
The present invention relates to the use of integrin antagonists in the treatment and/or prevention of dry age-related macular degeneration (AMD) or geographic atrophy (GA), the use of a pharmaceutical composition comprising said integri...
|
|
WO/2021/163610A1 |
Active agents that bind to VEGF or a VEGF receptor and reduce the severity of a condition associated with BLB disruption and/or angiogenesis, for example anti-VEGF antibodies or tyrosine kinase inhibitor small molecules, can be locally, ...
|
|
WO/2021/160813A1 |
The present invention relates to the field of pharmaceutical compositions for ocular diseases, in particular, retinal neurogenerative diseases. The invention provides pharmaceutical compositions to be applied topically in the eyes, inclu...
|
|
WO/2021/160716A1 |
Heteroaromatic carboxamides of formula (I), wherein R, R1, A1, A2, L1, and L2 are as defined in the description and the claims, and pharmaceutically acceptable salts thereof can be used in methods for the treatment of diseases which can ...
|
|
WO/2021/160718A1 |
Heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined in the description and the claims, and pharmaceutically acceptable salts thereof can be used in methods for the treatment of diseases which can be influenced...
|
|
WO/2021/160602A1 |
3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with ...
|
|
WO/2021/161230A1 |
The present invention relates to compounds of formula (I). The compounds maybe used to antagonise the Stimulator of Interferon Genes (STING) protein and may thereby treat liver fibrosis, fatty liver disease, non-alcoholic steatohepatitis...
|
|
WO/2021/163452A1 |
Nutritionally acceptable non-lipid compositions and methods are presented that modulate lipid metabolism, and especially increase LPC concentrations. Consequently, the compositions and methods presented herein will facilitate DHA transpo...
|
|
WO/2021/157730A1 |
[Problem] To provide a nucleic acid drug for treating or preventing illness or symptoms associated with expression of the p53 gene. [Solution] The present inventors have identified antisense oligonucleotides (ASOs) which act on a p53 gen...
|
|
WO/2021/156275A1 |
The invention relates to ophthalmic compositions comprising a nitric oxide releasing phosphodiesterase type 5 inhibitor (NO-PDE5 inhibitor) and a prostaglandin analog, and to the use of these ophthalmic compositions for the treatment of ...
|
|
WO/2021/158466A1 |
The present invention provides methods of treating refractive ocular conditions and related complications using compounds of Formula (I) and pharmaceutical compositions thereof either alone or in combination other active agents.
|
|
WO/2021/158219A1 |
Described are compounds, compositions, and methods suitable for diagnosing individuals with eye injuries and/or diseases. The compounds of the present disclosure have fluorescent groups and bis-dipicolylamine groups, which may be substit...
|
|
WO/2021/156813A2 |
The present invention relates to formulations for ophthalmic use characterized by a reduced dosage regimen.
|
|
WO/2021/158936A1 |
N-(3-Substituted thiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxami
des and N-(3-substituted oxazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamid
es (I) and (II) are disclosed. The compounds activate Yap and inhibit Lat...
|
|
WO/2021/157613A1 |
Provided is a compound having a voltage-dependent anion channel (VDAC) binding capacity. This pyrazole derivative having a VDAC-binding capacity is represented by formula (I). In the formula, R1 and R3 each independently represent an opt...
|
|
WO/2021/158589A1 |
The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human Son of Sevenless 2 (S...
|
|
WO/2021/156856A1 |
A novel composition for topical treatment, alleviation, and prevention of Occupational Dry Eye, Computer Vision Syndrome and Meibomian Gland Dysfunctions. The composition comprises an aqueous solution of a salt of an anionic polymer and ...
|
|
WO/2021/157968A1 |
The present invention relates to a controlled-release formulation for hearing loss and a preparation method therefor, and, more specifically, to a controlled-release formulation for hearing loss and a preparation method therefor, the for...
|
|
WO/2021/156435A1 |
The present invention relates to mucoadhesive solid or semisolid ocular delivery systems comprising a matrix of preactivated thiomers, preferably under the form of ocular inserts or ocular films. The ocular delivery systems of the invent...
|
|
WO/2021/156584A1 |
A compound of formula (I) and related aspects.
|
|
WO/2021/157681A1 |
The present invention provides a therapeutic agent effective against subretinal hyperreflective material or retinal disorders accompanying subretinal hyperreflective material. Specifically, provided is a therapeutic agent for subretinal ...
|
|
WO/2021/157732A1 |
A composition for lysing at least one type of staphylococcus bacteria selected from the group consisting of Staphylococcus hyicus, Staphylococcus chromogenes, Staphylococcus simulans, Staphylococcus schleiferi, and Staphylococcus felis, ...
|
|
WO/2021/155781A1 |
The present invention relates to a benzene sulfonamide compound containing a five-membered heterocycle represented by formula (I), and an enantiomer, a diastereomer, and a racemate thereof and a mixture thereof, and a pharmaceutically ac...
|
|
WO/2021/155178A1 |
Eye drops for treating dry eye include serum extracted from whole blood. An example method includes collecting whole blood from one or more donors (e.g., allogenic whole blood); separating the whole blood to obtain a serum; applying radi...
|
|
WO/2021/154647A1 |
The invention relates to methods and compositions for treating or preventing drug-induced hearing loss.
|
|
WO/2021/153719A1 |
[Problem] To provide a medicinal composition having a novel use that comprises a dental pulp-derived pluripotent stem cell preparation available for humans. [Solution] A medicinal composition that comprises dental pulp-derived stem cells...
|
|
WO/2021/151865A1 |
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra1, Ra2, Ra4, Ra5, X1, X1a, A1 and A2 have the meaning as i...
|
|
WO/2021/154842A1 |
Provided herein are compounds having activity against TTR related conditions, and pharmaceutically accepted salts and solvates thereof. Also provided are methods of using the compounds for inhibiting and preventing TTR aggregation and/or...
|
|
WO/2021/149442A1 |
The present invention addresses the problem of providing an agent for preventing eye aging that is capable of preventing or suppressing cell death of retinal pigment epithelial cells and a decrease in retinal thickness due to aging, and ...
|
|
WO/2021/148763A1 |
The present invention relates to peptide antagonists or inhibitors of GEF-H1, pharmaceutical compositions comprising said antagonists, polynucleotides encoding said antagonists, vectors encoding said polynucleotides, uses of said antagon...
|
|
WO/2021/148845A1 |
The present invention relates to an ophthalmic composition comprising omega-3 fatty acids, Vitamin D3, Vitamin A or esters thereof and liposomes and to the methods for the preparation thereof. The present invention further relates to the...
|
|
WO/2021/151044A1 |
The present invention includes a method for using diNACA as a prodrug to deliver diNACA, NACA and NAC to a mammal for therapeutic purposes to prevent or treat diseases or disorders involving oxidative stress. The method includes any dise...
|
|
WO/2021/150850A1 |
Provided herein are adeno-associated viruses and methods for using same to treat or prevent disorders that affect the inner ear of a subject.
|
|
WO/2021/143827A1 |
Provided herein are compositions and methods for regenerating retinal ganglion cells (RGCs) from retinal neuron cells by activating transcription factors such as one or more of Atoh7, Brn3B, Sox4, Sox11, or Ils1. The retinal neuron cells...
|
|
WO/2021/145355A1 |
The present invention provides a pharmaceutical composition for treating myopia, preventing myopia, and/or suppressing progression of myopia, the pharmaceutical composition containing omidenepag or an ester thereof, or a salt of these, a...
|
|
WO/2021/145641A1 |
The present invention relates to an N-phenolbenzothiazol-2-amine compound inhibiting angiogenesis and having structural stability, and to a pharmaceutical composition containing same as an active ingredient. The N-phenolbenzothiazol-2-am...
|
|
WO/2021/145249A1 |
This method for producing a medical device having a base material and a hydrophilic polymer layer includes a step for heating, at 50-100°C, a solution containing: a base material placed in an alkaline solution and pretreated at 50-100°...
|
